USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Disruptive Technologies and Game-changing Companies in the Global Pharmaceutical Cell Banking Market
Disruptive Technologies and Game-changing Companies in the Global Pharmaceutical Cell Banking Market
Proprietary CMO Cell Culture Technology Platforms are Disrupting the In-house-outsourced Balance of Cell Banking Services
18-Jan-2017
North America
$1,500.00
Special Price $1,125.00 save 25 %
Description
This market insight on the global cell banking market analyses disruptive technologies and provides details on game-changing companies. Biopharmaceutical companies are increasingly partnering with CMOs and CROs to store their proprietary cell lines and develop new ones. With increased collaborations, CMOs are coming up with niche and specific services for cell line development and cell banking. They are focusing on providing gene to GMP services, thereby expanding their service portfolios. Mammalian cell culture technology is the highest-growing system across all other cell systems. With the increase in infectious diseases, the development of novel mammalian cell culture systems is expected to evolve. With the growing need for the proper storage of cultured cell banks, CMOs are developing long-term preservation techniques through continuous temperature monitoring. With the emergence of single-use technologies and new developments in cryopreservation technologies and upstream/downstream processes, the cell banking market is expected to experience robust growth, with the major share being captured by contractors as they specialise in new technologies. CMOs are turning towards emerging markets such as Asia-Pacific. However, issues with delivery, service, IP protection, and regulatory and product quality are curbing growth. The key companies covered in the study include SGS Life Sciences, Charles River Laboratories, Wuxi AppTech, BioReliance Corporation, Eurofins, and Lonza.
Table of Contents
Key Findings
Market Segment Overview
Transformation in the Industry Ecosystem
Industry Value Chain
Game-changing Companies
Cell Banking and Cell Line Development—Technology Trends
8 Big Market Themes for Cell Banking
Technology Process Overview—Biopharmaceutical Production
Technology Process Overview—Timelines of the End-to-End Services Provided by Multiple CMOs
Technology Process Overview—Cell Banking
Technology Process Overview—Cell Banking (continued)
Key Technology Trends—Cell Banking
Key Technologies—Perfusion Technology
Key Technologies—Single-use Technology
Single-use/Disposable Manufacturing Technology versus Traditional Large Capacity Stainless Steel Bioreactors
Key Technologies—Cryopreservation Reagents and Upstream & Downstream Processes
High Growth in Mammalian Cell Culture Technology
Mammalian Cell Culture Technology Platforms
Mammalian Cell Culture Technology Platforms (continued)
Microbial Cell Culture Technology
Key Companies by Region
Key Companies by Region (continued)
SGS Life Sciences
SGS Life Sciences (continued)
SGS Life Sciences (continued)
Charles River Laboratories
Charles River Laboratories (continued)
Charles River Laboratories (continued)
Wuxi AppTech
Wuxi AppTech (continued)
Wuxi AppTech (continued)
BioReliance Corporation
BioReliance Corporation (continued)
BioReliance Corporation (continued)
Eurofins Scientific
Eurofins Scientific (continued)
Eurofins Scientific (continued)
Lonza
Lonza (continued)
Lonza (continued)
Merger, Acquisition, and Partnership Assessment
Merger, Acquisition, and Partnership Assessment (continued)
4 Major Growth Opportunities
The Last Word
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
| No Index | No |
|---|---|
| Podcast | No |
| Author | Shweta Pankaj |
| Industries | Healthcare |
| WIP Number | 9AB9-00-64-00-00 |
| Is Prebook | No |